Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Elan merges drug delivery unit EDT with Alkermes; deal valued at $953mm

Executive Summary

After several years of mulling over a potential divestment or spin off, Irish drug maker Elan Corp. PLC has finally achieved closure for Elan Drug Technologies Inc.: Elan is merging the drug delivery subsidiary with Alkermes Inc. (therapeutics for CNS diseases, diabetes, and rheumatoid arthritis) in a deal valued at $953mm. Elan says the transaction will allow it to reduce the debt on its balance sheet by one-third and to put more resources into its bioneurology business, including gaining additional market share for the MS drug Tysabri.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies